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Introduction
Migraine headache was believed to be much less prev-
alent among Asians than in Western populations.1
However, many surveys involving Asians were limited
by flaws in methodology and case definition criteria.
Using a validated questionnaire, a population-based
survey conducted in Taiwan showed that the 1-year
prevalence of migraine was 9.1% (4.5% in men, 14.4%
in women).2 This figure is similar to those involving
Western populations.1
Sumatriptan is commonly prescribed to treat acute
migraine attacks.3 It was initially available as a subcu-
taneous injection, and then as an orally administered
tablet, and later as an intranasal spray. The intranasal
formulation allows patients to avoid injections while
providing more rapid absorption and slightly reducing
hepatic first-pass compared with oral administration.
Several clinical trials have evaluated the efficacy of 
intranasal sumatriptan in providing relief from migraine
attacks. Two dose-ranging studies showed that suma-
triptan 10 mg and 20 mg were significantly more effec-
tive than placebo, with the 20-mg dose emerging as
optimal.4
At present, there is a paucity of data regarding the
efficacy of intranasal sumatriptan in the acute treatment
of migraine in Asian patients. In a comprehensive re-
view involving 2,307 patients, only 7 were Asian.5 This
review showed that clinical trials involving triptans
consistently demonstrate efficacy across ethnic groups;
however, the relative magnitude of the benefit may
vary. Placebo response in triptan trials may have influ-
enced the demonstrated relative benefit of triptans in
Asians. A clinical trial evaluating the efficacy of eletrip-
tan in Japanese migraineurs showed that the placebo
group had a high headache relief rate (51%) at 2 hours
postdose.6 Consistency of this observation in other
Asian subpopulations may be explored.
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The primary objective of this study was to compare
the efficacy, including speed of effect onset, and the
safety and tolerability of intranasal sumatriptan 20 mg
with that of placebo in the acute treatment of migraine
among Taiwanese patients.
Methods
Patients
Patients from a neurologic outpatient clinic of a me-
dical center in Taipei, 18–65 years old, with a history
of migraine, with or without aura (as defined by the
International Headache Society criteria7), for the past
12 months were recruited into the study. Patients
were required to have experienced 1–6 episodes of
moderate to severe migraine attacks per month during
the last 3 months prior to study enrollment, and were
required to distinguish migraine from non-migraine
headaches.
Demographic data, current medical status, migraine
history and concurrent medications of eligible patients
were recorded. Patients were excluded from the study
if they had tension-type headaches for > 15 days in 
a month during the previous 12 months, had been
exposed to intranasal sumatriptan at least 3 months
prior to the study; or had a known hypersensitivity 
to sumatriptan. Patients receiving ergotamine- or
dihydroergotamine-containing prophylactic migraine
medication, monoamine oxidase inhibitors, or lithium
were also excluded. Other exclusion criteria included
the following: pregnancy; breastfeeding; abuse of opi-
ates or psychotropic drugs, whether current or during
the previous 2 years; abuse of ergotamine (defined as
> 10 mg weekly), whether current or during the previ-
ous 12 months; current abuse of alcohol or other drugs;
ischemic heart disease; coronary vasospasm; athero-
sclerotic disease; and treated or untreated hypertension.
Patients who normally received prophylactic migraine
medications were allowed to continue prophylaxis, pro-
vided that their prophylaxis regimen did not contain
ergotamine or dihydroergotamine.
Procedures
This was a single-center, randomized, double-blind,
placebo-controlled, parallel-group study. The study
protocol was approved by the hospital’s institutional
review board and the Taiwan Department of Health.
All patients provided their written informed consent
before study enrollment.
After screening, patients were randomized using a
computer-generated, parallel design by 1:1 ratio
(block size of 4) into 2 groups given either intranasal
sumatriptan 20-mg spray or a placebo spray with iden-
tical appearance. Patients were instructed to adminis-
ter a single intranasal dose at the onset of a moderate
or severe migraine attack, with or without aura. They
were also instructed to withhold the study medication
within 6 hours of taking an analgesic or an antiemetic.
If the headache resolved or improved to mild severity
within 2 hours after the first dose, but worsened to
moderate or severe intensity from 2 to 24 hours post-
dose, a second identical dose was allowed to treat the
recurrence. If patients experienced insufficient pain relief,
they were allowed to use their usual non-sumatriptan
rescue medications 120 minutes after administration
of the study medication.
Outcome assessments
Response to treatment and usage of rescue medication,
if any, were recorded on a diary card. Patients assessed
headache intensity and then recorded the pain rating
on a diary card using a 4-point pain scale (0 = no pain,
1 = mild pain, 2 = moderate pain, 3 = severe pain). This
was done immediately before administering the first
intranasal dose, and after 15, 30, 45, 60, 90 and 120
minutes. The following were also recorded on the diary
card: associated symptoms (e.g. nausea, vomiting, pho-
nophobia and photophobia); time to normal function
(a subjective feeling of “meaningful relief” of migraine
headache and/or associated symptoms); time to com-
plete relief of migraine (absence of pain and associated
symptoms); taste (very unpleasant, unpleasant, no taste,
pleasant or very pleasant); patient’s overall rating of
the study medication (very poor, poor, reasonable, good
or excellent); and adverse events.
Headache relief was defined as reduction in head-
ache pain intensity from moderate/severe (pain rating
of 2/3) to mild/no pain (1/0). The primary efficacy
endpoint was headache relief at 60 minutes. Secondary
efficacy endpoints included headache relief rates at 15,
30, 45, 90 and 120 minutes; percentages at each time
interval of headache-free patients (i.e. headache reso-
lution, no headache at all) and those with no nausea,
vomiting, photophobia or phonophobia; and percen-
tage of patients requiring rescue medication between
2 and 24 hours after receiving the study medication.
Patients were instructed to return to the clinic 24
hours after the final administration of the test drug to
return their diary card. Adverse events and biochemi-
cal profiles were also assessed during this visit.
Statistical analysis
Analysis was conducted on an intent-to-treat basis.
All statistical tests were 2-sided, with a significance level
of 0.05. Based on literature review, headache relief at
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2 hours was around 70% in the triptan group and 30%
in the placebo group.8 Therefore, it was estimated that
at least 23 evaluable patients in each group were needed
to detect the statistical difference between them at the
5% level of significance with 80% power. The χ2 test
was used to compare the primary efficacy endpoint of
rate of headache relief at 60 minutes postdose. Secon-
dary endpoints were compared using the χ2 or Fisher’s
exact tests. The median times to functional recovery and
complete recovery were compared by nonparametric
Mann-Whitney test, and the interquartile range (the
distance between the 75th percentile and the 25th per-
centile) was also provided. The percentage of patients
taking a second dose of study medication to treat recur-
rence, percentage of patients experiencing relief after
the second dose of study medication, and taste rating
were described but not subjected to statistical analysis.
Results
Patient characteristics
A total of 60 patients were enrolled in the study and
randomized to receive treatment with sumatriptan nasal
spray or placebo (Figure 1). Among these patients, 
4 were withdrawn from the study: 2 from the suma-
triptan group and 2 from the placebo group. One 
patient in the sumatriptan group failed to take the
study medication within 6 weeks, which warranted
withdrawal according to the protocol; the other pa-
tient was misdiagnosed (headache was secondary to
an arteriovenous malformation rupture). In the placebo
group, 1 patient failed to take the study medication
within 6 weeks while the other patient lost the diary
card. The remaining 56 patients who received the study
medication and completed the diary record comprised
the intent-to-treat cohort. Table 1 shows the demo-
graphic data and baseline headache profiles of both
groups. The baseline characteristics of the sumatriptan
group did not differ significantly from those of the
placebo group. Among the 46 subjects who received
prophylactic medications, 35 (76%) received atenolol,
17 (46%) amitriptyline, 7 (15%) flunarizine, 2 (4%) imip-
ramine and 1 (2%) valproic acid. The distribution of
these medications did not differ between the treatment
and placebo groups.
Of the 56 patients, 53 (26 patients in the suma-
triptan group and 27 patients in the placebo group)
followed the study procedure completely. One patient
in the sumatriptan group and another in the placebo
group received analgesics prior to administering the
study medication during a migraine episode. One pa-
tient in the sumatriptan group took rescue medica-
tion within 2 hours of receiving the study drug. At the
time of administration of the study medication, the
sumatriptan group demonstrated a non-significantly
higher severe-to-moderate headache intensity ratio
than the placebo group, as well as higher frequencies
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Assessed for eligibility (n = 66)
Randomization
Assigned to intranasal sumatriptan
20 mg (n = 30)
• Was able to administer test medication
 (n = 29)
• Failed to administer the study medication
 within 6 wk (n = 1)
Excluded (n = 6) 
• Not meeting inclusion
 criteria (n = 5) 
• Other reasons (n = 1)
Assigned to placebo
(n = 30)
• Was able to administer placebo
 (n = 29)
• Failed to administer the study medication
 within 6 wk (n = 1)
Analyzed (n = 28)
Excluded from efficacy analysis
(n = 1) due to wrong diagnosis
Analyzed (n = 28)
Excluded from efficacy analysis
(n = 1) due to loss of diary card
Enrollment
Figure 1. Patient flow through the trial.
of associated migraine symptoms (with the exception
of aura) (Table 2).
Efficacy
Headache relief
One hour after dosing, 61% (17/28) of sumatriptan
nasal spray recipients experienced headache relief com-
pared with 43% (12/28) of placebo recipients (p =
0.181). A significant difference (p < 0.05) in headache
relief rates between the 2 groups was observed as
early as 30 minutes postdose (Figure 2). After adjust-
ing for differences in headache severity at the time of
treatment administration, and comparing using gen-
eral linear model analyses, a significant difference in
relief rates was also observed at 45 minutes (p=0.026).
The difference in headache relief rates between groups
diminished over time. Two hours after dosing, 60% of
sumatriptan nasal spray recipients reported headache
relief compared with 54% in the placebo group (p =
0.671). Furthermore, the sumatriptan group tended
to have less use of rescue medication than the placebo
group, but the difference failed to achieve statistical
significance.
Headache resolution
The percentages of patients who were completely free
of headache at all time intervals are shown in Figure 3.
At 90 minutes postdose, patients receiving sumatrip-
tan nasal spray were more likely to achieve complete
headache relief than placebo recipients (29% vs. 7%,
p = 0.036).
Recurrence
Among those who achieved headache relief after 2
hours, 7 patients experienced recurrence within 24
hours: 3 (19%) in the sumatriptan group and 4 (27%)
in the placebo group. Among those who received a
second dose for recurrence, 67% (2/3) experienced
relief 2 hours after the second dose in the sumatrip-
tan group, while 25% (1/4) experienced relief in the
placebo group.
Associated symptoms
The rates of resolution of nausea, phonophobia and
photophobia among those who had these symptoms
at the time of initial dosing did not differ between the
sumatriptan and placebo recipients. The infrequent
occurrence of vomiting in the placebo group (n = 1)
precluded meaningful comparison between the 2
groups.
Time to recovery
The median time to functional recovery following
sumatriptan nasal spray administration was 60 minutes
(interquartile range, 125) compared with 209 minutes
(interquartile range, 326.25) after placebo (Mann-
Whitney test, p=0.015). The median times to complete
recovery were 175 (interquartile range, 524.5) and
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Table 1. Demographic data and baseline headache characteristics of participants with migraine
Sumatriptan (n = 28) Placebo (n = 28) p*
Gender (female/male) 26/2 22/6 0.252
Age, yr (mean ± SD) 37.0 ± 10.8 37.4 ± 9.8 0.619
Aura (with/without) 4/24 3/25 1.000
Intensity (severe/moderate) 25/3 24/4 1.000
Duration of migraine history, yr (mean ± SD) 14.1 ± 9.7 12.2 ± 10.4 0.482
Attacks per month (mean ± SD) 2.7 ± 1.4 3.0 ± 1.5 0.399
Use of medications for migraine prevention 22 24 0.485
*Comparisons between sumatriptan and placebo groups were performed with the t test, χ2 test or Fisher’s exact test where appropriate.
Table 2. Headache characteristics at the time of study medication administration
Sumatriptan (n = 28) Placebo (n = 28) p*
Headache characteristic, n (%)
Intensity (severe/moderate) 13/15 (46/54) 8/20 (29/71) 0.168
Nausea 18 (64) 13 (46) 0.179
Vomiting 6 (21) 1 (4) 0.101
Photophobia 16 (57) 9 (32) 0.060
Phonophobia 20 (71) 16 (57) 0.265
Aura 2 (7) 4 (14) 0.669
*Comparisons between sumatriptan and placebo groups were performed with the χ2 test or Fisher’s exact test where appropriate.
475 minutes (interquartile range, 728.75), respectively,
for the 2 groups (Mann-Whitney test, p = 0.018).
Overall rating
A total of 39% of sumatriptan nasal spray recipients
and 21% of those treated with placebo rated the study
medication as good or excellent for the treatment of
migraine (p = 0.146).
Safety and tolerability
Eighty-three percent of the sumatriptan nasal spray
group rated the taste of the test medication as 
unpleasant or very unpleasant. The overall incidence
of patients reporting at least 1 adverse event was
65.5% (n=19) in the sumatriptan nasal spray group and
41.4% (n = 12) in the placebo group (p = 0.065).
Data from all 58 patients who administered the
study medication were used in evaluating adverse events.
These adverse events were mostly mild and transient,
and none were considered serious. The most commonly
reported sumatriptan-related adverse event was bitter
taste (21%) (Table 3). With the exception of taste dis-
turbance, the adverse event profile of sumatriptan nasal
spray was similar to that of placebo. Only 1 patient in
the sumatriptan nasal spray group complained of
chest tightness.
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Figure 2. Percentage of patients with migraine experiencing headache relief following administration of intranasal sumatriptan or
placebo. *p < 0.05 vs. placebo.
Figure 3. Percentage of headache-free patients at all time intervals, following intranasal administration of sumatriptan or placebo.
*p < 0.05 vs. placebo.
Discussion
The results of this randomized double-blind, placebo-
controlled trial demonstrated that sumatriptan 20-mg
nasal spray is a rapidly effective and well-tolerated treat-
ment for patients with acute migraine attacks. After
60 minutes, 61% of patients treated with sumatriptan
nasal spray experienced headache relief. A significant
difference from the effects of treatment with placebo
was observed at 30 minutes. Nausea, photophobia and
phonophobia were alleviated in the majority of patients
in the sumatriptan nasal spray group, although the
benefit in comparison to placebo did not reach statis-
tical significance. Most of the adverse events reported
in the sumatriptan group were mild and transient,
and none were considered serious.
The demographic data and baseline headache char-
acteristics of the 2 treatment groups were similar upon
enrollment into the trial, indicating successful ran-
domization. However, the headache profile of patients
at the time of drug administration seemed to be more
severe in sumatriptan recipients, probably because of
the small sample size. After adjustment for headache
severity at the time of drug administration, a signifi-
cant difference in relief rates between groups was also
observed at 45 minutes postdose.
With respect to response rates following sumatrip-
tan nasal spray administration, the results of this study
were similar to those of 2 large-scale, randomized,
placebo-controlled clinical trials conducted in the
United States (46–48% in 60 minutes, 62–63% in 120
minutes).9 This was also the case with response rates,
in terms of headache relief, headache elimination, and
improvement of nausea, photophobia and phonopho-
bia, reported in a review of 5 large-scale trials, the US
trials included.10 A retrospective analysis of intranasal
sumatriptan trials demonstrated that headache relief
rates from intranasal sumatriptan were not affected in
a clinically significant way by race.5 With the current
scarcity of Asian data concerning the clinical use of
intranasal sumatriptan, the present study may serve as
a reference for future Asian triptan studies.
Despite the high response rates observed in the
active arm of the present study, the benefits of sumatrip-
tan nasal spray treatment over placebo failed to reach
statistical significance in several efficacy parameters. This
may be partly due to the high efficacy rates observed
in the group treated with placebo. However, the small
sample size in this study should also be taken into
consideration. A review showed that in pain trials, treat-
ment with placebo produced a standard mean differ-
ence of 27% (95% confidence interval, 15–40%) when
compared with no treatment.11 In previous placebo-
controlled intranasal sumatriptan trials largely con-
ducted in Western populations, the relief rates with
placebo were 30% at 1 hour and 25–36% at 2 hours.4,9,10
In the present study, however, the placebo group de-
monstrated headache relief rates of 43% at 1 hour and
54% at 2 hours. A similar phenomenon was observed
in another Asian oral triptan trial. In a Japanese trial
investigating eletriptan for migraine, the placebo group
reported a 51% headache response rate at 2 hours,
whereas placebo response rates in Western eletriptan
trials were from 22% to 24%.12 The reason for the
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Table 3. Summary of reported adverse events in participants 
following administration of intranasal sumatriptan or placebo
Sumatriptan Placebo 
(n = 29) (n = 29)
Bitter taste 6 0
Vomiting* 4 1
Nasal discomfort 4 0
Worsening of headache 2 0
Muscle soreness 2 0
Dizziness 1 2
Weakness 1 1
Palpitations 1 1
Throat discomfort 1 1
Anxiety 0 2
Photosensitivity 1 0
Chest tightness 1 0
Epigastric pain 1 0
Diarrhea 1 0
Wet nostrils 1 0
Nasal stuffiness 1 0
Difficulty opening mouth 1 0
Syncopal attack 1 0
Fatigue 1 0
Chills 1 0
Sweating 1 0
Tremors 1 0
Cough 1 0
Bone pain 1 0
Allergy 1 0
Toothache 1 0
Scalp numbness 1 0
Nausea 0 1
Insomnia 0 1
Flushing 0 1
Tonsil inflammation 0 1
Vocal cord inflammation 0 1
Heat sensation in throat 0 1
Swelling of the head 0 1
Total number of patients 19 12
reporting adverse events
*Including vomiting due to bitter taste.
higher placebo response in the present study was un-
clear, although lower headache severity in the placebo
group compared with the sumatriptan group may be
a factor. Previous triptan exposure may also influence
placebo response, but this was not accounted for in
the present study. The magnitude of pain relief from
placebo is strongly associated with expectancy of pain
relief, conditioning, and whether analgesia was assessed
concurrently or retrospectively, hence suggesting a
psychologic aspect to the placebo effect.12,13 With
high placebo rates observed in both the present study
and the Japanese eletriptan trial,6 a relation between
ethnicity and the magnitude of the placebo effect may
be surmised and should be a focus of investigation. 
A review on placebo responses in oral triptan trials
indicate that geographic location does not significantly
account for placebo response, but this review only com-
pared North American trials with European trials.14
However, the study did demonstrate a wide variability
in placebo response rates (range, 17–50%). This sup-
ports the premise that placebo response may be influ-
enced by several factors. Together with the high placebo
rate in the present trial, this highlights the importance
of recruiting a placebo group in acute migraine trials.15
After intranasal administration, sumatriptan is di-
rectly and rapidly absorbed, with 60% of the maximum
plasma concentration (Cmax) occurring at 30 minutes
after administration of a single 20mg dose. Sumatriptan
is bound to plasma proteins to a low extent, 14–21%.
Sumatriptan is cleared predominately through metab-
olism by monoamine oxidase enzymes.16 Its major me-
tabolite, an indoleacetic analog, has no 5-HT1 activity.
Pharmacokinetics of oral or subcutaneous sumatrip-
tan are not affected by ethyl alcohol, dihydroergota-
mine, propranolol, flunarizine, pizotifen, butorphanol,
clarithromycin, ethinylestradiol and norethindrone, 
by the “second-generation” triptans such as aldnitan
or naratriptan, or by the selective serotonin reuptake
inhibitor paroxetine, to a clinically significant extent.17
Because MAO-A inhibitors can increase plasma con-
centration of sumatriptan, they were contraindicated in
this trial. Although the percentage of patients on pre-
ventive medications was high in this study, the drug-
drug interaction might not play a role in the evaluation
of the efficacy of intranasal sumatriptan.
In line with a previous review of sumatriptan intra-
nasal studies,10 taste disturbance, vomiting and nasal
discomfort were the 3 most common adverse events in
sumatriptan recipients. Taste disturbance was expect-
edly the most commonly reported adverse experience
with intranasal sumatriptan, but this may be of relatively
minor importance since previous studies have reported
that patients consider taste to be unimportant in the
choice of an antimigraine medication.10 It is likely
that certain potentially drug-related events, such as
vomiting and worsening of headaches, may be symp-
toms of migraine attack itself. The frequencies of nau-
sea or vomiting and nasal discomfort in our study
were 13.8% and 13.8%, respectively; whereas those in
a review of 5 clinical trials were 13.5% for nausea and
vomiting and 3.8% for nasal discomfort.18 However,
it is difficult to make meaningful comparisons of these 2
adverse events since the number of subjects in the study
was small. Nevertheless, the trend is similar to the results
of other international studies. Although none of the
patients who received placebo reported taste distur-
bance, 41% reported at least 1 adverse event. This figure
is higher than those reported by placebo groups in
other studies.19 Most of the reported adverse events in
the placebo group were features associated with
migraine attacks or anxiety.
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